FDA Grants Orphan Drug Status to GamaMabs’ GM102 for Treatment of Gynecological Cancers

FDA Grants Orphan Drug Status to GamaMabs’ GM102 for Treatment of Gynecological Cancers
The U.S. Food and Drug Administration granted orphan drug status to GamaMabs Pharma’s investigative therapy GM102 for the treatment of gynecological cancers, including ovarian, fallopian tube, and primary peritoneal cancers. The designation is expected to support the development of the therapy candidate, which targets rare cancers that affect approximately 175,000 women in the U.S. Orphan drug

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *